UNITED
STATES
SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549












FORM
10-Q












[] QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934



For
the quarterly period ended March 31, 2018



or



[  ] TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934



For
the transition period from __________________ to _______________________



Commission
file number: 000-15746



VIRTUAL
CRYPTO TECHNOLOGIES, INC.(Exact Name Of Registrant As Specified In Its Charter)



|Delaware                                     |  | 68-0080601                                   
|-------------------------------------------- |  | ---------------------------------------------
|(State
    of Incorporation)                 |  | (I.R.S.
    Employer 
    Identification No.)
|                                             |  |                                              
|11
    Ha’amal Street, Tel Aviv, Israel      |  | 4809174                                      
|(Address
    of Principal Executive Offices) |  | (ZIP
    Code)                               



Registrant’s
Telephone Number, Including Area Code: +972 3-600-3375



Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [  ]
No [X]



Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer (as defined in
Rule 12b-2 of the Exchange Act) or a smaller reporting company.



|Large
    accelerated filer | [  ]                                               |                             | Accelerated
    filer         | [  ]
|--------------------------- | -------------------------------------------------- | --------------------------- | ----------------------------- | ----
|Non-accelerated
    filer   | [  ]
(Do not check if a smaller reporting company) |                             | Smaller
    reporting company | [X] 
|                            |                                                    | Emerging
    growth company | [  ]                         



If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]



Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No
[X]



On
May 21, 2018, the registrant had 63,722,843 shares of common stock issued and outstanding.


















VIRTUAL
CRYPTO TECHNOLOGIES, INC.



TABLE
OF CONTENTS



|Item         |  | Description                                                    |  | Page
|------------ |  | -------------------------------------------------------------- |  | ----
|             |  |                                                                |  |     
|             |  | PART I - FINANCIAL INFORMATION                                 |  |     
|             |  |                                                                |  |     
|ITEM
    1.  |  | FINANCIAL STATEMENTS                                           |  | 3   
|ITEM
    2.  |  | MANAGEMENT’S DISCUSSION AND ANALYSIS AND RESULTS OF OPERATIONS |  | 4   
|ITEM
    3.  |  | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK     |  | 6   
|ITEM
    4.  |  | CONTROLS AND PROCEDURES                                        |  | 7   
|             |  |                                                                |  |     
|             |  | PART II - OTHER INFORMATION                                    |  |     
|             |  |                                                                |  |     
|ITEM
    1.  |  | LEGAL PROCEEDINGS                                              |  | 8   
|ITEM
    1A. |  | RISK FACTORS                                                   |  | 8   
|ITEM
    2.  |  | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS    |  | 8   
|ITEM
    3.  |  | DEFAULT UPON SENIOR SECURITIES                                 |  | 9   
|ITEM
    4.  |  | MINE SAFETY DISCLOSURE                                         |  | 9   
|ITEM
    5.  |  | OTHER INFORMATION                                              |  | 9   
|ITEM
    6.  |  | EXHIBITS                                                       |  | 9   
|             |  | SIGNATURES                                                     |  | 11  







2







PART
I - FINANCIAL INFORMATION



ITEM
1. FINANCIAL STATEMENTS



|Balance Sheets as of March 31, 2018 (Unaudited) and December 31, 2017                                                                          | F-1
|---------------------------------------------------------------------------------------------------------------------------------------------- | ---
|Statements of Comprehensive Loss for the Three Months Ended March 31, 2018 and 2017 (Unaudited)                                                | F-2
|Statements of Changes in Stockholders’ Equity (Deficit) for the Three Months Ended March 31, 2018 (Unaudited) and Year Ended December 31, 2017 | F-3
|Statements of Cash Flows for the Three Months Ended March 31, 2018 and 2017 (Unaudited)                                                        | F-4
|Notes to Unaudited Interim Financial Statements                                                                                                | F-5



3







Virtual
Crypto Technologies, Inc.

(Formerly
Emerald Medical Applications Corp)

Balance
Sheets



|                                                                                                                                                                                        |  | March 31, 2018 |            |   | December 31, 2017 |  
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  | -------------- | ---------- | - | ----------------- | -
|                                                                                                                                                                                        |  | (Unaudited)    |            |   |                   |  
|Assets                                                                                                                                                                                  |  |                |            |   |                   |  
|Current assets:                                                                                                                                                                         |  |                |            |   |                   |  
|Cash and cash equivalents                                                                                                                                                               |  | $              | 1,449,795  |   |                   | $
|Other receivables                                                                                                                                                                       |  |                | -          |   |                   |  
|Assets held for sale (Note 6)                                                                                                                                                           |  |                | 28,703     |   |                   |  
|Total current assets                                                                                                                                                                    |  |                | 1,478,498  |   |                   |  
|                                                                                                                                                                                        |  |                |            |   |                   |  
|Restricted cash                                                                                                                                                                         |  |                | -          |   |                   |  
|Fixed assets, net of accumulated depreciation of $26,120 at December 31, 2017                                                                                                           |  |                | -          |   |                   |  
|Total assets                                                                                                                                                                            |  | $              | 1,478,498  |   |                   | $
|                                                                                                                                                                                        |  |                |            |   |                   |  
|Liabilities and Stockholders’ Equity (Deficit)                                                                                                                                          |  |                |            |   |                   |  
|Current liabilities:                                                                                                                                                                    |  |                |            |   |                   |  
|Accounts payable and accrued liabilities                                                                                                                                                |  | $              | 206,304    |   |                   | $
|Accounts payable - related party                                                                                                                                                        |  |                | -          |   |                   |  
|Deferred revenues                                                                                                                                                                       |  |                | 50,000     |   |                   |  
|Employee payable                                                                                                                                                                        |  |                | 16,667     |   |                   |  
|Accrued interest payable (Note 3)                                                                                                                                                       |  |                | 1,922      |   |                   |  
|Short term portion of convertible notes (Note 3)                                                                                                                                        |  |                | 186,412    |   |                   |  
|Liabilities held for sale(*) (Note 6)                                                                                                                                                   |  |                | 459,965    |   |                   |  
|Total current liabilities                                                                                                                                                               |  |                | 921,270    |   |                   |  
|                                                                                                                                                                                        |  |                |            |   |                   |  
|Convertible notes (Note 3)                                                                                                                                                              |  |                | -          |   |                   |  
|Total liabilities                                                                                                                                                                       |  |                | -          |   |                   |  
|                                                                                                                                                                                        |  |                | 21,999,798 |   |                   |  
|Stockholders’ deficit                                                                                                                                                                   |  |                |            |   |                   |  
|Preferred stock, $0.0001 par value; 10,000,000 shares authorized; none and 529 Series A shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively.            |  |                | -          |   |                   |  
|Common stock, $0.0001 par value; 490,000,000 shares authorized; 22,543,008 and 59,205,162 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively. (Note 4) |  |                | 5,821      |   |                   |  
|Accumulated other comprehensive income                                                                                                                                                  |  |                | (19,337    | ) |                   |  
|Additional paid-in capital (Note 4)                                                                                                                                                     |  |                | 37,876,289 |   |                   |  
|Receipt on account of shares (Note 4)                                                                                                                                                   |  |                | 117,150    |   |                   |  
|Accumulated deficit                                                                                                                                                                     |  |                | (37422,795 | ) |                   |  
|Total stockholders’ equity (deficit)                                                                                                                                                    |  |                | 557,227    |   |                   |  
|Total liabilities and stockholders’ equity (deficit)                                                                                                                                    |  | $              | 1,478,497  |   |                   | $



(*)
Includes $82.331 payable to a related party.



The
accompanying notes are an integral part of these interim financial statements.



F-1







Virtual
Crypto Technologies, Inc.

(Formerly
Emerald Medical Applications Corp)

Statements
of Comprehensive Loss

For
the Three Months ended March 31, 2018 and 2017

(Unaudited)



|                                                        |  | Three months   |             |   | Three months   |  
|------------------------------------------------------- |  | -------------- | ----------- | - | -------------- | -
|                                                        |  | ended          |             |   | ended          |  
|                                                        |  | March
31, 2018 |             |   | March 31, 2017 |  
|                                                        |  |                |             |   |                |  
|                                                        |  |                |             |   |                |  
|Expenses:                                               |  |                |             |   |                |  
|Research and development                                |  |                | 54,011      |   |                |  
|Sales and marketing                                     |  |                | 310,000     |   |                |  
|General and administrative                              |  |                | 1,064,283   |   |                |  
|Total operating expenses                                |  |                | 1,428,294   |   |                |  
|Loss from continuing operations                         |  |                | (1,428,294  | ) |                |  
|Finance expense. net                                    |  |                | (19,374,082 | ) |                |  
|Net loss from continuing operations                     |  | $              | (20,802,376 | ) |                | $
|Loss from discontinued operations (Note 6)              |  |                | -           |   |                |  
|Net loss from continuing operations                     |  | $              | (20,802,376 | ) |                | $
|Basic and diluted net loss per share                    |  |                |             |   |                |  
|From continuing operations                              |  | $              | (0.51       | ) |                | $
|From discontinued operations                            |  | $              | (0.00       | ) |                | $
|Total basic and diluted net loss per share              |  | $              | (0.48       | ) |                | $
|Weighted average shares outstanding - basic and diluted |  |                | 41,048,456  |   |                |  



The
accompanying notes are an integral part of these interim financial statements.



F-2







Virtual
Crypto Technologies, Inc.

(Formerly
Emerald Medical Applications Corp)

Statement
of Changes in Stockholders’ Equity (Deficit)

For
the Three MonthsEnded March 31, 2018 and the Year Ended December 31, 2017

(Unaudited)





|                                                                      |  | Common |            |  | Preferred |   |       | Additional Paid-in |  |  | Receipt on Account of |   |  | Other Comprehensive |     |  | Accumulated |   |            | Total stockholders’ | 
|--------------------------------------------------------------------- |  | ------ | ---------- |  | --------- | - | ----- | ------------------ |  |  | --------------------- | - |  | ------------------- | --- |  | ----------- | - | ---------- | ------------------- | 
|                                                                      |  | Shares |            |  | Amount    |   |       | Stock              |  |  | Amount                |   |  | Capital             |     |  | Shares      |   |            | Income              | 
|Balance as of December 31, 2016                                       |  |        | 19,931,478 |  |           | $ | 1,994 |                    |  |  | -                     |   |  | $                   | -   |  |             | $ | 13,826,957 |                     | 
|Common stock issued for cash                                          |  |        | 1,315,563  |  |           |   | 132   |                    |  |  | -                     |   |  |                     | -   |  |             |   | 526,081    |                     | 
|Cashless exercise of Warrants                                         |  |        | 1,096,395  |  |           |   | 110   |                    |  |  | -                     |   |  |                     | -   |  |             |   | (110       | )                   | 
|Conversion of Convertible Note to shares                              |  |        | 74,572     |  |           |   | 7     |                    |  |  | -                     |   |  |                     | -   |  |             |   | 10,393     |                     | 
|Issuance of Ordinary Shares                                           |  |        | 125,000    |  |           |   | 12    |                    |  |  | -                     |   |  |                     | -   |  |             |   | (12        | )                   | 
|Issuance of Preferred Stock                                           |  |        | -          |  |           |   | -     |                    |  |  | 529                   |   |  |                     | (*) |  |             |   | 529,000    |                     | 
|Receipt on Account of Shares                                          |  |        |            |  |           |   |       |                    |  |  | -                     |   |  |                     | -   |  |             |   | -          |                     | 
|Share based compensation                                              |  |        | -          |  |           |   | -     |                    |  |  | -                     |   |  |                     | -   |  |             |   | 76,616     |                     | 
|Net loss for the year                                                 |  |        | -          |  |           |   | -     |                    |  |  | -                     |   |  |                     | -   |  |             |   | -          |                     | 
|Balance as of December 31, 2017                                       |  |        | 22,543,008 |  |           | $ | 2,255 |                    |  |  | 529                   |   |  | $                   | -   |  |             | $ | 14,968,925 |                     | 
|Common stock and warrants issued for cash                             |  |        | 23,876,427 |  |           |   | 2,388 |                    |  |  | -                     |   |  |                     | -   |  |             |   | 1,671,412  |                     | 
|Common stock issued for services                                      |  |        | 3,629,999  |  |           |   | 363   |                    |  |  | -                     |   |  |                     | -   |  |             |   | 891,937    |                     | 
|Warrants issued for services                                          |  |        | -          |  |           |   | -     |                    |  |  | -                     |   |  |                     | -   |  |             |   | 39,845     |                     | 
|Exercise of stock options                                             |  |        | 62,500     |  |           |   | 6     |                    |  |  | -                     |   |  |                     | -   |  |             |   | 57         |                     | 
|Issuance of new convertible note with a beneficial conversion feature |  |        | -          |  |           |   | -     |                    |  |  | -                     |   |  |                     | -   |  |             |   | 100,000    |                     | 
|Partial conversion of new convertible notes to shares                 |  |        | 300,000    |  |           |   | 30    |                    |  |  | -                     |   |  |                     | -   |  |             |   | 2,970      |                     | 
|Change is the terms of Convertible Note                               |  |        | -          |  |           |   | -     |                    |  |  | -                     |   |  |                     | -   |  |             |   | 20,189,804 |                     | 
|Partial conversion of convertible note to shares                      |  |        | 8,221,800  |  |           |   | 822   |                    |  |  | -                     |   |  |                     | -   |  |             |   | 81,396     |                     | 
|Cancellation of Preferred Shares                                      |  |        | -          |  |           |   | -     |                    |  |  | (529                  | ) |  |                     | -   |  |             |   | (150,000   | )                   | 
|Receipt on Account of Shares                                          |  |        | 571,429    |  |           |   | -     |                    |  |  | -                     |   |  |                     | -   |  |             |   | -          |                     | 
|Issuance of Shares in respect of proceeds received during 2017        |  |        | -          |  |           |   | 57    |                    |  |  | -                     |   |  |                     | -   |  |             |   | 79,943     |                     | 
|Net loss for the period                                               |  |        | -          |  |           |   | -     |                    |  |  | -                     |   |  |                     | -   |  |             |   | -          |                     | 
|Balance as of March 31, 2018                                          |  |        | 59,205,163 |  |           | $ | 5,921 |                    |  |  | -                     |   |  | $                   | -   |  |             | $ | 37,876,289 |                     | 





The
accompanying notes are an integral part of these interim financial statements.



F-3







Virtual
Crypto Technologies Inc (Formerly Emerald Medical Applications Corp)

Statements
of Cash Flows

For
the Three Months Ended March 31, 2018 and 2017

(Unaudited)



|                                                                                 |  | Three months   |             |   | Three months   |  
|-------------------------------------------------------------------------------- |  | -------------- | ----------- | - | -------------- | -
|                                                                                 |  | ended          |             |   | ended          |  
|                                                                                 |  | March 31, 2018 |             |   | March 31, 2017 |  
|Operating Activities:                                                            |  |                |             |   |                |  
|                                                                                 |  |                |             |   |                |  
|Net loss                                                                         |  | $              | (20,802,376 | ) |                | $
|Shares issued for services                                                       |  |                | 892,300     |   |                |  
|Finance loss arising from change in terms of convertible notes                   |  |                | 20,165,406  |   |                |  
|Share based compensation                                                         |  |                | -           |   |                |  
|Increase in net liabilities for sale                                             |  |                | 445,611     |   |                |  
|Increase (Decrease) in accounts payable and accrued expenses                     |  |                | (321,158    | ) |                |  
|Decrease in employees payable                                                    |  |                | -           |   |                |  
|Decrease in amounts due from related party                                       |  |                | (721,530    | ) |                |  
|Increase in deferred revenues                                                    |  |                | 50,000      |   |                |  
|Increase (decrease) in accrued interest                                          |  |                | (65,924     | ) |                |  
|Increase (decrease) in other receivables                                         |  |                | 12,122      |   |                |  
|Net cash used in continuing operating activities                                 |  |                | (345,449    | ) |                |  
|                                                                                 |  |                |             |   |                |  
|Net change in non-cash working capital items relating to discontinued operations |  |                | -           |   |                |  
|                                                                                 |  |                |             |   |                |  
|Net change in investment activities relating to discontinued operation           |  |                | -           |   |                |  
|                                                                                 |  |                |             |   |                |  
|Financing Activities:                                                            |  |                |             |   |                |  
|Proceeds from sale of common stock and warrants (net of issuance expenses)       |  |                | 1,575,072   |   |                |  
|Exercise of options                                                              |  |                | 63          |   |                |  
|Issuance of Shares in respect of proceeds received during 2017                   |  |                | 117,150     |   |                |  
|Issuance of convertible note                                                     |  |                | 100,000     |   |                |  
|Net cash provided by financing activities                                        |  |                | 1,792,285   |   |                |  
|                                                                                 |  |                |             |   |                |  
|Net increase in cash                                                             |  |                | 1,446,836   |   |                |  
|Cash and cash equivalents - beginning of period                                  |  |                | 2,959       |   |                |  
|Cash and cash equivalents - end of period                                        |  | $              | 1,449,795   |   |                | $
|                                                                                 |  |                |             |   |                |  
|Non-cash transactions:                                                           |  |                |             |   |                |  
|Conversion to shares of convertible loans                                        |  |                | 85,218      |   |                |  
|Cancellation of preferredshares                                                  |  |                | (150,000    | ) |                |  



The
accompanying notes are an integral part of these financial statements.



F-4







Virtual
Crypto Technologies, Inc.

(Formerly
Emerald Medical Applications Corp)

For
the Three Months Ended March 31, 2018 and 2017

Notes
to Financial Statements

(Unaudited)



Note
1. The Company and Significant Accounting Policies.



Organizational
Background:



Virtual
Crypto Technologies, Inc. (f/k/a Emerald Medical Applications Corp) (the “Company,” “Registrant,” “we,”
“us” or “our”), was incorporated in the State of Ohio in 1989 under a predecessor name, Zaxis International
Inc. (“Zaxis”). On August 25, 1995, Zaxis merged with a subsidiary of The InFerGene Company, a Delaware corporation,
which entity changed its name to “Zaxis International, Inc.” and the Company was reincorporated in Delaware as Zaxis.
On December 30, 2014, Zaxis entered into a Memorandum of Understanding with Emerald Medical Applications Ltd., which was then
a private limited liability company incorporated under the laws of the State of Israel (“Emerald Israel” or “Emerald”).
On March 16, 2015, Zaxis and Emerald Israel executed the Share Exchange Agreement, which closed on July 14, 2015 (the “Share
Exchange Agreement”), and the Company continued the operations of Emerald Israel as it sole operating activities under its
then current name “Zaxis International, Inc.” During the fourth quarter of 2015, in connection with such share exchange,
the Company changed its name to “Emerald Medical Applications Corp.” The Share Exchange Agreement was accounted for
as a reverse recapitalization. As a result, the historical financial statements of the Registrant were replaced with the historical
financial statements of Emerald Israel.



New
Business Developments



On
January 17, 2018, the Company formed a new wholly owned subsidiary under the laws of the State of Israel, Virtual Crypto Technologies
Ltd. (the “Subsidiary”), to develop and market software and hardware products facilitating, allowing and supporting
purchase and/or sale of cryptocurrencies through ATMs, tablets, personal computers (“PCs”) and/or mobile devices.



Cessation
of Former Operations



On
January 29, 2018, the Company ceased the DermaCompare operations of its former subsidiary, Emerald Israel, and on May 2, 2018,
the District Court of Lod gave a winding-up order for Emerald Israel and nominated an Israeli advocate as a special executor to
Emerald Israel. To the extent that the liquidation procedure yields proceeds in excess of Emerald Israel’s current obligations,
the first $250,000 will be distributed to the previous shareholders of the Company’s preferred stock (see Note 3) and any
excess thereafter, to the Company. However, based on the Company’s current best estimate, it is not anticipated that such
excess proceeds will be achieved. See Note 6. Discontinued Operations.



Going
Concern:



The
Company has incurred significant operating losses and negative cash flows from operating activities in relation to its DermaCompare
operations, since incorporation. The Company raised approximately $1.9 million in the first quarter of 2018, however, it will
be required to obtain additional liquidity resources in order to support the commercialization of its new operations and maintain
its research and development activities. The Company is addressing its liquidity needs by seeking additional funding from public
and/or private sources. There are no assurances, however, that the Company will be able to obtain an adequate level of financial
resources that are required for the short and long-term requirements.



These
conditions raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial
statements do not include any adjustments to reflect the possible future effects on recoverability and classification of assets
or the amounts and classification of liabilities that may result from the outcome of this uncertainty.



Basis
of Presentation and Significant Accounting Policies:



The
accompanying unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiary,
the Subsidiary, prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”)
and with the instructions to Form 10-Q. The financial statements presented herein have not been audited by an independent registered
public accounting firm but include all material adjustments (consisting of normal recurring adjustments) which are, in the opinion
of management, necessary for a fair statement of the financial condition, results of operations and cash flows for the period.
However, these results are not necessarily indicative of results for any other interim period or for the full fiscal year. The
preparation of financial statements in conformity with GAAP requires us to make certain estimates and assumptions for the reporting
periods covered by the financial statements. These estimates and assumptions affect the reported amounts of assets, liabilities,
revenues and expenses. Actual amounts could differ from these estimates.



F-5







Certain
information and footnote disclosures normally included in financial statements in accordance with generally accepted accounting
principles have been omitted pursuant to the rules of the Securities and Exchange Commission (“SEC”). The accompanying
unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and notes
thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the SEC on April 17,
2018 (the “Annual Report”).



Recent
Accounting Pronouncements



The
Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on its
financial statements. Following are newly issued standards or material updates to the Company’s previous assessments from
its Annual Report:



In
May 2014, the Financial Accounting Standards Board (the “FASB”) issued a new standard to achieve a consistent application
of revenue recognition within the U.S., resulting in a single revenue model to be applied by reporting companies under GAAP. Under
the new model, recognition of revenue occurs when a customer obtains control of the promised goods or services in an amount that
reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the
new standard requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows
arising from contracts with customers. The new standard is effective with respect to the Company beginning in the first quarter
of 2018; early adoption is prohibited. The new standard is required to be applied retrospectively to each prior reporting period
presented or retrospectively with the cumulative effect of initially applying it recognized at the date of initial application.
As the Company has not incurred revenues to date, it does not expect the new standard to have a material impact on its consolidated
financial statements.



In
February 2016, the FASB issued a new lease accounting standard requiring the recognition of lease assets and liabilities on the
balance sheet. This standard is effective beginning in the first quarter of 2019; early adoption is permitted. The Company does
not expect the adoption of this standard to have a material impact on its consolidated financial statements. As the Company currently
is not a party to any leasing arrangement, it does not expect the new standard to have a material impact on its consolidated financial
statements.



In
June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial
Instruments.” With respect to assets measured at amortized cost, such as held-to-maturity assets, the update requires presentation
of the amortized cost net of a credit loss allowance. The update eliminates the probable initial recognition threshold that was
previously required prior to recognizing a credit loss on financial instruments. The credit loss estimate can now reflect an entity’s
current estimate of all future expected credit losses as opposed to the previous standard, when an entity only considered past
events and current conditions. With respect to available for sale debt securities, the update requires that credit losses be presented
as an allowance rather than as a write-down. The update is effective beginning in the first quarter of 2020; early adoption is
permitted. As the Company has insignificant receivable balances, the Company does not expect the adoption of this standard to
have a material impact on its consolidated financial statements.



In
July 2017, the FASB issued ASU 2017-11, which includes Part I “Accounting for Certain Financial Instruments with Down Round
Features” and Part II “Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of
Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-Controlling Interests With a Scope Exception”. The ASU
makes limited changes to the Board’s guidance on classifying certain financial instruments as either liabilities or equity.
The ASU’s objective is to improve (1) the accounting for instruments with “down-round” provisions and (2) the
readability of the guidance in ASC 480 on distinguishing liabilities from equity by replacing the indefinite deferral of certain
pending content with scope exceptions. This standard is effective beginning in the first quarter of 2019; early adoption is permitted.
The Company early adopted the standard, retrospectively, for each prior period presented in the financial statements included
elsewhere herein.



Note
2. Deferred Revenues.



On
January 24, 2018, the Company’s subsidiary, entered into a binding term sheet (the “Chiron Term Sheet”) with
Chiron Refineries Ltd. (“Chiron”), a public company listed on the Tel-Aviv Stock Exchange (TASE: CHR). Pursuant to
the Chiron Term Sheet, (i) Virtual Crypto Israel shall appoint a wholly-owned subsidiary of Chiron, under the laws of the Turkish
Republic of Northern Cyprus, as the exclusive distributor of Virtual Crypto Israel’s Products in the territory of the Republic
of Turkey, including the territory of Turkish Republic of Northern Cyprus (the “Territory”); and (ii) such distributor
shall have the right to appoint sub-distributors within the Territory. The appointment of the Chiron subsidiary as distributor
is subject to the payment by the distributor of $250,000 to the Company as an appointment fee, of which $150,000 shall be deemed
an advance payment by the distributor made on account of future purchases of our Products.



During
the three months ended March 31, 2018, the Company received $50,000 on account of the appointment fee, which has been recorded
as deferred revenues on our balance sheets.



F-6







Note
3. Notes Payable.



Notes
payable and accrued interest as of March 31, 2018 and December 31, 2017 are as follows:



|                 |  | March31, 2018 |          |   | December 31, 2017 |  
|---------------- |  | ------------- | -------- | - | ----------------- | -
|                 |  |               |          |   |                   |  
|Principle        |  | $             | 973,394  |   |                   | $
|Discount         |  |               | (786,982 | ) |                   |  
|Accrued interest |  |               | 1,924    |   |                   |  
|Total            |  |               | 188,336  |   |                   |  



Issuances
of convertibles notes during the first quarter of 2018



From
January 16,2018 through January 23, 2018, the Company received from certain third parties an aggregate amount of $100,000 as consideration
for the Company’s issuance of convertible promissory notes in the aggregate principal amount of $100,000 (the “Notes”)
(i) bearing interest at the rate of 1% per annum; (ii) with a conversion price of $0.01 per share of common stock; and (iii) repayable
through to January 15, 2019. The beneficial conversion feature was valued at $100,000, which resulted in a $100,000 discount recorded
as a reduction of debt and an increase to additional paid in capital in the Statement of Shareholders’ Equity (Deficit).
The discount is amortized to finance expenses in the Statement of Comprehensive Loss over the term of the Notes. On January 23,
2018, $3,000 of the Notes was converted at $0.01 per share into 300,000 shares, based upon the Notes conversion price of $0.01
per share of common stock.



Transfer
and change of ownership of convertible notes during the first quarter of 2018



On
January 24, 2018, Alpha Anstalt Capital (“Alpha”), Chi Squared Capital (“Chi”), Firstfire Global Opportunities
Fund LTC, Goldmed Ltd, Ilan Malca and Maz Partners (together the “Sellers”) sold their convertible notes totaling
$956,209 (the “January 2018 Convertible Notes”) to certain new third-party investors (“New Investors”).
On the same day, the Company and the New Investors agreed to(i) amend the conversion price of the January 2018 Convertible Notes
from $0.014 to $0.01 (ii) to cancel the Class A warrants and Class B warrants issued together with the January 2018 Convertible
Notes (the “Cancelled Warrants”) (see Note 4. Stockholders’ Equity. for accounting treatment of the Cancelled
Warrants), (iii) to amend the interest rate from 8% to 1% per annum under the January 2018 Convertible Notes; (iv) to extend the
repayment date to January 23, 2019, and (iv) to cancel the option granted to Alpha and Chi in July 2016 (“Alpha Chi Option”).



The
change in terms of the January 2018 Convertible Notes, including the cancellation of the warrants was accounted for as an extinguishment
of the convertible notes and the issuance of new convertible notes. The Company recorded a finance expense in the amount of 18,415,471in
the Statement of Comprehensive Loss and an increase to Additional Paid-in Capital in the Statement of Shareholder’ Equity
(Deficit) of $21.6 million as a result of the transaction.



The
Company further concluded that the post amended convertible notes contain a beneficial conversion feature equal to the par value
of the January 2018 Convertible Notes ($956,209) and accordingly recorded a discount on the January 2018 Convertible Notes, to
be amortized to finance expense in the Statement of Comprehensive Loss over the term of the January 2018 Convertible Notes.



The
Company accounted for the Alpha Chi Option as derivative liabilities that are measured at their far value at each period end,
with changes in fair value recorded as finance expense or income. The fair value of the Alpha Chi Option at December 31, 2017
was nil, and at the date of cancellation was $2,186,629. The Company recorded a finance loss of $2,186,629 during the period from
December 31, 2017 through the extinguishment date of the Alpha Chi Option as a result of the change in the fair value of the derivative
liability.



On
January 24, 2018, $73,000 of the January 2018 Convertible Notes were converted at a conversion price of $0.01 per share into 7,300,000
shares of the Company’s common stock and on March 19, 2018, a further $9,218 of the January 2018 Convertible Loans were
converted at a conversion price of $0.01 per shares into 921,800 shares of the Company’s common stock.



Non-convertible
note



On
July 8, 2014, the Company issued a convertible note to Axel Springer Plug & Play Accelerator GmbH in the amount of $29,719.
Accrued interest as of March 31, 2018 and December 31, 2017 amounted to $3,316. In terms of the original agreement, as of March
31, 2018 and December 31, 2017, the convertible note is no longer convertible.



Note
4. Stockholders’ Equity.



Shares
of the Company’s common stock confer upon their holders the right to receive notice to participate and vote in general meetings
of shareholders of the Company, the right to receive dividends, if declared, and the right to receive a distribution of any surplus
of assets upon liquidation of the Company.



Shares
of the Company’s preferred stock confer upon their holders the right to receive dividends when paid to holders of common
stock of the Company on an as-converted basis, and the right to receive a distribution of any surplus of assets upon liquidation
of the Company before any distribution or payment shall be made to the holders of any common stock.



F-7







Changes
in Shares of Preferred Stock During the First Quarter of 2018



On
January 4, 2018, the Company, Emerald Israel, Alpha Capital Ansalt (“Alpha”) and Chi Squared Inc. (“Chi,”
and Alpha and Chi together, the “Preferred Shareholders”), entered into an agreement pursuant to which the Preferred
Shareholders agreed to cancel their shares of Series A Preferred Convertible Stock in return for the receipt of up to $250,000
of proceeds from the liquidation of Emerald Israel, to the extent that such liquidation yields net positive proceeds (“Excess
Net Assets”). As such, as of March 31, 2018, there were no shares of Series A Preferred Convertible Stock outstanding. Management’s
best estimate of the potential value of the Excess Net Assets at the date of the cancellation of the shares of Series A Preferred
Convertible Stock was $150,000 and therefore, the Company recorded a charge to Additional Paid-in Capital in the Statement of
Changes in Shareholders’ Equity (Deficit) with a corresponding credit to liabilities. Management’s best estimate of
the potential value of the Excess Net Assets as of March 31, 2018, was nil. Accordingly, the Company recorded a finance income
of $150,000 in its Statement of Comprehensive Loss a result of the reversal of the relating liability.



Issuances
of Shares of Common Stock During the First Quarter of 2018



During
the first quarter of 2018, the Company received the aggregate amount of $1,673,800 from “accredited investors” in
consideration for the issuance of 23,876,427 units (the “Units”) at an offering price of $0.07 per Unit, with each
Unit consisting of: (i) one share of the Company’s common stock (the “Shares”); (ii) one common stock purchase
warrant exercisable for a period of twelve months to purchase one additional Share at an exercise price of $0.14per share (“Class
F Warrant”); and (iii) one (1) common stock purchase warrant exercisable for a period of twelve months to purchase one additional
Share at an exercise price of $0.28 per share (“Class G Warrant”) (the “$0.07 Unit Offering”). The offer
and sale of the Units, without registration under the Securities Act of 1933, as amended (the “Act”), was made in
reliance upon the exemption provided by Section 4(2) of the Act and/or Regulation S and Regulation D promulgated thereunder.



In
addition, during March 2018, an additional $117,150 was received from other “accredited investors” under the $0.07
Unit Offering, who subscribed for 571,429 Units, which were issued in April 2018 and are reflected as Receipt on Account of Shares
in the Statement of Changes in Stockholders’ Equity as of March 31, 2018.



On
February 8, 2018, the Company issued 571,429 units to two accredited investors in respect of $80,000 which was received in August
2017 (the “August 2017 Financing”). Each Unit comprised (i) one share of the Company’s common stock; (ii) one
Class A warrant exercisable into one shares of the Company’s common stock at a price of $0.14 per share within 12 months
for the issuance date; and (iii) one Class B warrant exercisable into one share of the Company’s common stock at a price
of $0.14 per share within 24 months for the issuance date.



On
March 12, 2018, the Company issued a total of 3,629,999 restricted shares of its common stock to certain consultants in connection
with services rendered during the first quarter of 2018, which shares were valued at $901,902, based on the closing share price
on the day prior to each of the issuances. The above-mentioned amount was recorded as a charge to the Company’s Statement
of Comprehensive Loss, with a corresponding credit to Additional Paid in Capital in the Company’s Statement of Changes in
Stockholders’ Equity.



On
March 20, 2018, the Company issued a total of 62,500 restricted shares of its common stock in consideration for the exercise of
a stock option at an exercise price of $0.01 per share, which options were granted in connection with services rendered in October
2016. The Company recorded the proceeds on the exercise of the stock option in Additional Paid-in Capital in its Statement of
Comprehensive Equity (Deficit).



As
described in Note 3. Notes Payable, the Company issued a total of 8,521,800 shares of its common stock in respect of the conversion
of $3,000 of the Notes and $73,000 and $9,218 of the January 2018 Convertible Notes.



Warrants



As
described in Note 3. Notes Payable, 6,334,626 Class A warrants and 5,400,478 Class B warrants were cancelled during the first
quarter of 2018 (“Cancelled Warrants”), in connection with the change in terms of the convertible notes.

As
described above in this Note 4. Stockholders’ Equity, the Company issued 23,867,427 Class F and 23,867,427, Class G warrants
in respect of the $0.07 Unit Offering.

On
January 26, 2018, the Company signed a consulting agreement with Maz Partners, pursuant to which they are to provide investment
and corporate finance advice to the Company in consideration for 200,000 Class H warrants. Each Class H warrant is exercisable
into one share of the Company’s common stock at an exercise price of $0.14 per share and the warrants expire on January
2020. The period of the agreement is two years the effective date. The fair value of the Class H Warrants at the issuance date
was $43,829 and was charged to General and administration expenses in the Statement of Comprehensive Loss with a corresponding
credit to Additional Paid-in Capital in the Statement of Changes in Stockholders’ Equity (Deficit).



As
described above in this Note 4. Stockholders’ Equity, on February 8, 2018, the Company issued 571,429 Class B warrants and
571,429 Class B warrants in respect of the August 2017 Financing.



F-8







The
following table summarizes information of outstanding warrants issued to investors and consultants in exchange for their services
as of March 31, 2018:



|                               |  | Warrants |            |  | Warrant Term |  |              | Exercise Price |  |   | Exercisable | 
|------------------------------ |  | -------- | ---------- |  | ------------ |  | ------------ | -------------- |  | - | ----------- | 
|Investors – Class A Warrants   |  |          | 571,429    |  |              |  | August 2018  |                |  | $ | 0.14        | 
|Investors – Class B Warrants   |  |          | 571,429    |  |              |  | August 2019  |                |  | $ | 0.14        | 
|Alimi Ahmed - Class E Warrants |  |          | 900,000    |  |              |  |              | (1)            |  | $ | 0.0001      | 
|Investors – Class F Warrants   |  |          | 23,867,427 |  |              |  | January 2019 |                |  | $ | 0.14        | 
|Investors – Class G Warrants   |  |          | 23,867,427 |  |              |  | January 2019 |                |  | $ | 0.14        | 
|Investors - Class H Warrants   |  |          | 200,000    |  |              |  | January 2020 |                |  | $ | 0.14        | 



(1)
During 2015, a total of 2,700,000 Class E Warrants were issued by the Company to Lior Wayn pursuant to the terms of the Share
Exchange Agreement and were exercisable in three equal tranches of 900,000 Shares each (the “Tranches”) at an exercise
price of $0.0001 per share of the Company’s common stock, subject to and within 45 days of the Company achieving the milestones
defined in the Share Exchange Agreement. On December 16, 2016, the Company terminated Lior Wayn’s employment agreements
with the Company and Emerald Israel, and removed him as an executive officer and director. During 2017, Mr. Wayn transferred,
sold and assigned his 5,212,878 shares of the Company’s common stock and 900,000 Class E Warrants that were fully-vested
to an entity controlled by Mr. Alimi Ahmed, then a member of the Company’s Board of Directors. Effective as of December
31, 2016, the remaining 1,800,000 Class E Warrants that had been issued to Mr. Wayn were canceled.



Employee
Stock Options



A
summary of the Company’s activity related to issuances of options to the Company’s employees, executives, directors
and consultants and related information is as follows:



|                                                 |  | For
        the three month period ended
        March
        31, 2018 |          |  | For
        the year ended
        December
        31, 2017 | 
|------------------------------------------------ |  | ----------------------------------------------------------------------- | -------- |  | ------------------------------------------------------------ | 
|                                                 |  | Amount
    of options                                                   |          |  | Weighted
    average exercise price                          | 
|                                                 |  |                                                                         |          |  | $                                                            | 
|Outstanding
    at beginning of year             |  |                                                                         | 62,500   |  |                                                              | 
|Granted                                          |  |                                                                         |          |  |                                                              | 
|Exercised                                        |  |                                                                         | (62,500) |  |                                                              | 
|Cancelled                                        |  |                                                                         | -        |  |                                                              | 
|                                                 |  |                                                                         |          |  |                                                              | 
|Outstanding
    at the end of period             |  |                                                                         | -        |  |                                                              | 
|Vested
    and expected-to-vest at end of period |  |                                                                         | -        |  |                                                              | 



The
aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the fair market value
of the Company’s shares of common stock on March 31, 2018 and December 31, 2017, respectively, and the exercise price, multiplied
by the number of in-the-money stock options on those dates) that would have been received by the stock option holders had all
stock option holders exercised their stock options on those dates.



The
stock options outstanding as of March 31, 2018, and December 31, 2017, have been separated into exercise prices, as follows:



|Exercise price |      |  | Stock options outstanding as of |  |        | Weighted average remaining contractual life – years as of |  |  | Stock options exercisable as of | 
|-------------- | ---- |  | ------------------------------- |  | ------ | --------------------------------------------------------- |  |  | ------------------------------- | 
|               |      |  | March 31, 2018                  |  |        | December 31, 2017                                         |  |  | March 31, 2018                  | 
|               |      |  |                                 |  |        |                                                           |  |  |                                 | 
|               | 0.01 |  |                                 |  | 62,500 |                                                           |  |  | 62,500                          | 
|               |      |  |                                 |  | 62,500 |                                                           |  |  | 62,500                          | 



Compensation
expense recorded by the Company in respect of its stock-based employee compensation awards in accordance with ASC 718-10 for the
three month period ended March 31, 2018 and 2017 was nil and $58,650, respectively.



F-9







Note
5. Related Party Transactions.



Other
than transactions and balances related to cash and share based compensation to the Company’s officers and directors, the
issuances of convertible debt and warrants to Alpha and as otherwise set forth herein, the Company did not have any transactions
and balances with related parties and executive officers during the three months ended March 31, 2018 and 2017.



As
a result of the issuance of the Notes (see Note 2) and the acquisition by the New Investors of certain convertible notes (see
Note 2), certain New Investors may hold convertible notes allowing them to convert the notes in excess of 5% of the Company’s
issued and outstanding shares of common stock. Accordingly, such New Investors may be deemed to be related parties under Item
404(a) of Regulation S-K. In addition, certain New Investors receive fees for consulting services provided to the Company, none
of which were incurred during the first quarter ended March 31, 2018.



Note
6. Discontinued Operations.



On
January 29, 2018, the Company ceased the DermaCompare operations of its former subsidiary, Emerald Israel, and on May 2, 2018,
the District Court of Lod gave a winding-up order for Emerald Israel and nominated an Israeli advocate as a special executor to
Emerald Israel. To the extent that the liquidation procedure yield proceeds in excess of Emerald Israel’s current obligations,
the first $250,000 will be distributed to the previous shareholders of the Company’s preferred stock (see Note 3. Notes
Payable) and any excess thereafter, to the Company. However, based on the Company’s current best estimate, it is not anticipated
that such excess proceeds will be achieved.



As
such, financial results of Emerald Israel are presented as net loss from discontinued operations on the Consolidated Statements
of Comprehensive Loss for the three months ended March 31, 2018 and 2017; and assets and liabilities of Emerald Israel to be disposed
of are presented as Assets held for sale and Liabilities held for sale on the Consolidated Balance Sheet as of March 31, 2018.



Note
7. Subsequent Events.



On
April 20, 2018, the Company issued 700,000 shares of its common stock to two former directors in respect of services provided
by during the second quarter ended June 30, 2018.





F-10









ITEM
2. MANAGEMENT’S DISCUSSION AND ANALYSIS AND RESULTS OF OPERATIONS

Special
Note Regarding Forward-Looking Statements



The
following management’s discussion and analysis section should be read in conjunction with the Company’s unaudited
financial statements as of March 31, 2018 and 2017, and the relatedstatements of comprehensive loss, statement of changes
in stockholders’ equity (deficit) and statements of cash flows for the three months then ended, and the related notes thereto
contained in this Quarterly Report on Form 10-Q (this “Quarterly Report”). This management’s discussion and
analysis section contains forward-looking statements, such as statements of the Company’s plans, objectives, expectations
and intentions. Any statements that are not statements of historical fact are forward-looking statements. When used, the words
“believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,”
“expect” and the like, and/or future tense or conditional constructions “will,” “may,” “could,”
“should,” etc., or similar expressions, identify certain of these forward-looking statements. These forward-looking
statements are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed
or implied by the forward-looking statements. These factors include those contained in section captioned “Risk Factors”
of the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on
April 17, 2018 (the “Annual Report”). The Company’s actual results could differ materially from those contemplated
in these forward-looking statements as a result of these factors. The Company does not undertake any obligation to update forward-looking
statements to reflect events or circumstances occurring after the date of this Quarterly Report.



Business
Overview



On
January 17, 2018, the Company formed a new wholly owned subsidiary under the laws of the State of Israel, Virtual Crypto Technologies
Ltd. (the “Subsidiary”), to develop and market software and hardware products facilitating, allowing and supporting
purchase and/or sale of cryptocurrencies through ATMs, tablets, personal computers (“PCs”) and/or mobile devices.
On January 29, 2018, the Company ceased the DermaCompare operations of its former subsidiary, Emerald Israel, and on May 2, 2018,
the District Court of Lod gave a winding-up order for Emerald Israel and nominated an Israeli advocate as a special executor to
Emerald Israel.



In
March 2018, the Company changed its name from “Emerald Medical Applications Corp.” to “Virtual Crypto Technologies,
Inc.” to reflect its new operations and business focus, and the Company’s trading symbol changed from MRLA to VRCP
on the OTCQB.



Plan
of Operations and Recent Developments



The
following plan of operation provides information which management believes is relevant to an assessment and understanding of the
Company’s results of operations and financial condition. The discussion should be read along with the Company’s financial
statements and notes thereto included elsewhere in this Quarterly Report.



On
January 17, 2018, the Company formed Virtual Crypto Technologies Ltd. as a new wholly-owned subsidiary under the laws of the State
of Israel (“Virtual Crypto Israel”) and reported the appointment of Mr. Alon Dayan as CEO of the new subsidiary. Virtual
Crypto Israel was formed to develop and market software and hardware products facilitating, allowing and supporting purchase and/or
sale of cryptocurrencies through ATMs, tablets, personal computers (“PCs”) and/or mobile devices (the “Products”).



In
March 2018, the Company changed its name from “Emerald Medical Applications Corp.” to “Virtual Crypto Technologies,
Inc.” to reflect its new operations and business focus, and the Company’s trading symbol changed from MRLA to VRCP
on the OTCQB.



The
Company, through its fully owned Israeli subsidiary Virtual Crypto Israel, has developed the NetoBit Trader, a proprietary, Cryptographic
algorithmic technology that it is able to confirm in real-time the purchase or sale of any cryptocurrency. The Company’s
NetoBit products dramatically improve the cryptocurrency trading experience with faster execution and lower costs, setting a new
time to transaction standard, trading in seconds rather the industry norm of 20 minutes. Because of its speed, the Company’s
customers enjoy the best crypto exchange rate at the point of transaction. The Company is marketing its NetoBit Trader software
and hardware products for the purchase and sale of cryptocurrencies through ATMs, tablets, PCs and/or mobile devices (collectively,
the “VC Products”). The Company further believes that the ability to immediately confirm cryptocurrency transactions
in real-time should be a major competitive breakthrough in making the purchase and sale of cryptocurrencies user friendly.



The
Company filed a Current Report on Form 8-K on January 24, 2018, reporting that through Virtual Crypto Israel subsidiary, it entered
into a binding term sheet (the “Chiron Term Sheet”) with Chiron Refineries Ltd. (“Chiron”), a public company
listed on the Tel-Aviv Stock Exchange (TASE: CHR). Pursuant to the Chiron Term Sheet (i) Virtual Crypto Israel, shall appoint
a wholly-owned subsidiary of Chiron, under the laws of the Turkish Republic of Northern Cyprus, as the exclusive distributor of
Virtual Crypto Israel’s Products in the territory of the Republic of Turkey, including the territory of Turkish Republic
of Northern Cyprus (the “Territory”); and (ii) the distributor shall have the right to appoint sub-distributors within
the Territory. The appointment of the Chiron subsidiary as distributor is subject to the payment by the distributor to Virtual
Crypto Israel of $250,000 as an appointment fee, of which $150,000 shall be deemed an advance payment by the distributor made
on account of future purchases of the Company’s Products.



The
Company further granted such distributor an option, exercisable by the Distributor within 12 months from the date on which the
ATM Product, including the related software and hardware, is fully tested and ready for installation and operation, to be appointed
as an exclusive distributor of the Products for the Federal Republic of Nigeria. If the option is exercised, the distributor shall
pay Virtual Crypto Israel an appointment fee not higher than $250,000.To date, $50,000 has been paid by such distributor to Virtual
Crypto Israel.



4







The
appointment of such distributor is subject to the payment by the distributor to Virtual Crypto Israel of US$250,000 (the “Appointment
Fee”). An amount of $150,000 of the total Appointment Fee shall be deemed an advance payment by the Distributor, made on
account of future purchases of the Company’s Products and related services.



As
a result of the foregoing, the disclosure under “Results of Operations During the Three Months Ended March 31, 2018 As Compared
to the Three Months Ended March 31, 2017” is not comparable and should not be relied upon in evaluating or understanding
the Company. Reference is made to the disclosure under “Note 11. Subsequent Events” included in the Company’s
Annual.



Results
of Operations During the Three Months Ended March 31, 2018 As Compared to the Three Months Ended March 31, 2017



Our
research and development expenses were $54,011 for the three months ended March 31, 2018, as compared to nil during the same period
in the prior year. The increase was due to research and development expenses in the development for our virtual crypto products.



Our
general and administrative expenses increased to $1,064,283 for the three months ended March 31, 2017 as compared to $68,650 during
the same period in the prior year. The significant increase was due to non-cash consulting expenses paid by way of issuances of
the Company’s shares and warrants to certain consultants who assisted in the establishment of the new business.



Interest
expense increased to $19,374,082 for the three months ended March 31, 2018, as compared $198,450 during the same period in the
prior year. The significant increase during the period in 2018 was primarily as a result of the changes of the terms of certain
convertible notes that occurred during the three months ended March 31, 2018.



Financing
Activities During the Three-Month Period Ended March 31, 2018



Issuance
of equity during the three-month period ended March 31, 2018



During
the first quarter of 2018, the Company received the aggregate amount of $1,673,800 from “accredited investors” in
consideration for the issuance of 23,876,427 of the Company’s units (the “Units”), at an offering price of $0.07
per Unit, with each Unit consisting of: (i) one share of the Company’s common stock (the “Shares”); (ii) one
common stock purchase warrant exercisable for a period of twelve months to purchase one additional Share at an exercise price
of $0.14 per share (“Class F Warrant”); and (iii) one common stock purchase warrant exercisable for a period of twelve
months to purchase one additional Share at an exercise price of $0.28 per share (“Class G Warrant”) (the “$0.07
Unit Offering”). The offer and sale of the Units, without registration under the Securities Act of 1933, as amended (the
“Act”), was made in reliance upon the exemption provided by Section 4(2) of the Act and/or Regulation S and Regulation
D promulgated thereunder.



In
addition, during March 2018, an additional $117,150 was received from other “accredited investors” under the $0.07
Unit Offering, who subscribed from 571,429 Units, which were issued in April 2018 and are reflected as Receipt on Account of Shares
in the Statement of Changes in Stockholders’ Equity as of March 31, 2018.



On
February 8, 2018, the Company issued 571,429 units of the Company’s securities to two accredited investors in respect of
$80,000 which was received in August 2017 (“August 2017 Financing”). Each unit was comprised of (i) one share of the
Company’s common stock; (ii) one Class A warrant exercisable into one share of the Company’s common stock, at a price
of $0.14 per share, within 12 months for the issuance date; and (iii) one Class B warrant exercisable into one share of the Company’s
common stock, at a price of $0.14 per share, within 24 months for the issuance date.



On
March 12, 2018, the Company issued a total of 3,629,999 restricted shares to certain consultants in connection with services rendered
during the first quarter of 2018, which shares were valued at $901,902, based on the closing share price on the day prior to each
of the issuances. The above-mentioned amount was recorded as a charge to the Company’s Statement of Comprehensive Loss,
with a corresponding credit to Additional Paid in Capital in the Company’s Statement of Changes in Stockholders’ Equity.



On
March 20, 2018, the Company issued a total of 62,500 restricted shares of its common stock in consideration for the exercise of
a stock option at an exercise price of $0.01 per share, which option was granted in connection of certain services rendered in
October 2016.



In
March 2018, the Company issued a total of 921,800 shares of its common stock in respect of the conversion of $9,218 of the January
2018 Convertible Notes.



Issuance
of new convertible notes during the three-month period ended March 31, 2018



From
January 16,2018 through January 23, 2018, the Company received an aggregate amount of $100,000 as consideration for the issuance
of the Company’s convertible promissory notes with an aggregate principal amount of $100,000 (the “Notes”) (i)
bearing interest at the rate of 1% per annum; (ii) with a conversion price of $0.01 per share of the Company’s common stock;
and (iii) repayable through to January 15, 2019. 3,000 of the Notes were converted at a conversion price of $0.01 per share into
300,000 shares.



5







Liquidity
and Capital Resources



Our
balance sheet as of March 31, 2018 reflects current assets of $1,478,498 consisting of cash of $1,449,795 and assets held for
sale in respect of our discontinued operations of $28,703. We also have $921,270in current liabilities consisting of $206,304
in accounts payable and accrued liabilities, $50,000 of deferred revenues, $16,667 employee payable, $1,922 in accrued interest,
short-term portion of convertible notes of $186,412 and liabilities held of sale in respect of our discontinued operations of
$459,965. As of December 31, 2017, we had current assets of $15,181 consisting of $2,959 in cash and other receivables of $12,222.
As of December 31, 2017, we had fixed assets, net of $14,290, $1,011,941 in current liabilities consisting of $445,653 in accounts
payable and accrued liabilities, $82,331 in accounts payable to related party, $98,476 employee payable, $67,846 in accrued interest,
and short-term portion of convertible notes of $317,635.



We
had working capital of $557,228as of March 31, 2018, as compared to negative working capital of $996,760 at December 31, 2017.
Our total liabilities as of March 31, 2018 were $921,270, as compared to $1,618,106 at December 31, 2017.



During
the period ended March 31, 2018, we had negative cash flow from continuing operations of $345,449, which was the result of a net
loss of $20,802,376, increase in accrued interest and amortization of discount on convertible notes of $20,165,406 and $892,300shares
and warrants issued for services, offset by net changes in working capital of $600,799.



During
the three months ended March 31, 2018, we had no cash flow effect from investing activities.



During
the period ended March 31, 2018, we had positive cash flow from financing activities of $1,792,185, which was the result of $1,574,972
proceeds from issuance of equity, $117,150 of receipt on account of shares, $100,000 from the issuance of convertible notes and
$63 for the eservice of options.



There
are no limitations in the Company’s Certificate of Incorporation on the Company’s ability to borrow funds or raise
funds through the issuance of shares of its common stock to affect a business combination. The Company’s limited resources
and lack of having cash-generating business operations may make it difficult to borrow funds or raise capital. The Company’s
limitations to borrow funds or raise funds through the issuance of restricted capital stock required to effect or facilitate a
business combination may have a material adverse effect on the Company’s financial condition and future prospects, including
the ability to complete a business combination.



Until
such time as the Company can generate substantial revenues, the Company expects to finance its cash needs through a combination
of the sale of its equity and/or convertible debt securities, debt financing and strategic alliances and collaborations. The Company
does not have any committed external source of funds. To the extent that the Company raises additional capital through the sale
of its equity and/or convertible debt securities, the ownership interest of its stockholders will be diluted, and the terms of
these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt
financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions,
such as incurring additional debt, making capital expenditures or declaring dividends. To the extent that debt financing ultimately
proves to be available, any borrowing will subject us to various risks traditionally associated with indebtedness, including the
risks of interest rate fluctuations and insufficiency of cash flow to pay principal and interest, including debt of an acquired
business. If the Company raises funds through additional collaborations or strategic alliances with third parties, we may have
to relinquish valuable rights to our future revenue streams and/or distribution arrangements. No assurance can be given that any
future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. If the Company
is unable to raise additional funds through equity and/or debt financings when needed or on attractive terms, the Company may
be required to delay, limit, reduce or terminate the operations of some or all of its business segments.

The
Company has only limited capital. Additional financing is necessary for the Company to continue as a going concern. The Company’s
independent auditors have unqualified audit opinion for the period ended December 31, 2017 with an explanatory paragraph on going
concern.

In
view of these matters, realization of a major portion of the assets in the accompanying balance sheet is dependent upon continued
operations of the Company. Management believes that actions presently being taken to obtain additional equity financing will provide
the opportunity to continue as a going concern.



ITEM
3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK



Not
required for smaller reporting companies.



6







ITEM
4. CONTROLS AND PROCEDURES



Evaluation
of Disclosure Controls and Procedures



As
of March 31, 2018, the Company’s Chief Executive Officer and Chief Financial Officer conducted an evaluation (the “Evaluation”)
regarding the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e)
under the Exchange Act. Based upon the evaluation of these controls and procedures required by Rules 13a-15 or 15d-15, the Company’s
Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were
ineffective as of the end of March 31, 2018 under the Committee of Sponsoring Organizations of the Treadway Commission in Internal
Control-Integrated Framework (2013) because of certain material weaknesses. As of such date, the Company had neither the resources,
nor the personnel, to provide an adequate control environment.



Changes
in Internal Control Over Financial Reporting



There
were no changes in our internal control over financial reporting or in other factors identified in connection with the evaluation
required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during the quarter ended March 31, 2018 that have
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.



Inherent
Limitations on Effectiveness of Controls and Procedures



The
Company’s management, including our Chief Executive Officer and Chief Financial Officer, does not expect that the Company’s
disclosure controls and procedures or its internal controls will prevent all errors and all fraud. A control system, no matter
how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system
are met. The Company’s control systems are designed to provide such reasonable assurance of achieving their objectives.
Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls
must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls
can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected.
These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and
that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts
of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls
also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design
will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because
of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent
limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.



CEO
and CFO Certifications



Exhibits
31.1 and 31.2 to this Quarterly Report are the Certifications of the Company’s Chief Executive Officer and the Chief Financial
Officer, respectively. These Certifications are required in accordance with Section 302 of the Sarbanes-Oxley Act (the “Section
302 Certifications”). This Item 4 of this Quarterly Report, which you are currently reading, is the information concerning
the Evaluation referred to above and in the Section 302 Certifications and this information should be read in conjunction with
the Section 302 Certifications for a more complete understanding of the topics presented.



7







PART
II - OTHER INFORMATION



ITEM
1. LEGAL PROCEEDINGS



On
December 12, 2016, the Company filed a Current Report on Form 8-K reporting that at a meeting of its Board of Directors held on
November 18, 2016, at which meeting the majority of the Company’s Board of Directors authorized the termination of Lior
Wayn as CEO/president of the Company and of its wholly-owned Israeli subsidiary, Emerald Israel. The termination of Mr. Wayn as
an executive officer of the Company and Emerald Israel was “for cause” as described more fully in such Form 8-K. In
addition, the Form 8-K further reported that in connection with, Mr. Wayn’s termination as an executive officer, Mr. Wayn
was removed as a director of the Companying accordance with the provisions of Section 141(k) of the General Corporation Law of
the State of Delaware based upon the written consent of the holders of the majority of the Company’s shares of common stock
issued and outstanding at November 16, 2016.



In
April 2017, a lawsuit was filed with the Tel Aviv, Israel court by Mr. Wayn claiming certain damages to the total amount of $100,000,
under the assertion of wrongful dismissal by the Company and Emerald Israel. The Company believes these claims to be unsubstantiated
and wholly without merit and intends to vigorously defend itself against these claims. The Company believes that Mr. Wayn will
not be successful in his claim. Nevertheless, the Company believes that the outcome of the proceeding will not materially affect
the Company.



In
December 2017, a liquidation request was filed with the Tel Aviv District Court by a group of former employees of Emerald Israel,
under the assertion of delay of pay and insolvency. On December 20, 2017, at a hearing before the court, it was ordered that Emerald
Israel shall settle its pension debts to the former employees under applicable Israeli law within 21 days and settle its other
debts to them in 60 days, the failure of which would result in a winding-up order (the equivalent of a liquidation) being potentially
issued. Based on the collaboration of Emerald Israel and its former employees and the fact that the Company was in negotiation
with third-parties for the infusion of equity capital and has started negotiating the sale of certain assets, the Company’s
legal advisors believe that the liquidation claim will be dismissed by the court. The amounts being claimed by the former employees
were less than $96,000 and are included in current liabilities at March 31, 2018.



On
January 29, 2018, the Company transferred the ordinary shares of its former Israeli subsidiary, Emerald Israel, to Attorney Eviatar
Knoller, Esq., with offices at 20 Lincoln, Tel Aviv-Jaffa 6713412, as trustee (the “Trustee”). The purpose of the
transfer of the management shares to the Trustee, pursuant to resolution of the Registrant’s Board of Directors, was to
enable the Trustee to liquidate the management shares and/or the assets of Emerald Israel to satisfy its debts and satisfy its
financial obligations to former employees. As a result, the former employees of Emerald Israel commenced an action in a court
of competent jurisdiction in Israel to liquidate Emerald Israel and use any assets to satisfy the debts owed to the former employees.



On
April 24, 2018, Emerald Israel announced to the District Court of Lod, Tel Aviv about the failure in contracting a buyer for its
technology at market price and therefore that Emerald Israel is no longer opposed to the requested Liquidation Warrant. On May
1, 2018, the Official Receiver submitted its response to the court, stating that according to such announcement of Emerald Israel,
it did not oppose the requested Liquidation Warrant either. Based on both the Company’s and the Official Receiver’s
position, on May 2, 2018, the District Court of Lod has given a Winding-up Order in Emerald Israel’s file and temporarily
nominated Adv. Hanit Nov as a Special Executor to Emerald Ltd.



ITEM
1A. RISK FACTORS



See
risk factors discussed in Part I, “Item 1A. Risk Factors” in the Company’s Annual Report.



ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS



On
January 23, 2018, $3,000 of the Notes was converted at $0.01 per share into 300,000 shares, based upon the Notes conversion price
of $0.01 per share of common stock.



On
January 24, 2018, $73,000 of the January 2018 Convertible Notes were converted at a conversion price of $0.01 per share into 7,300,000
shares of the Company’s common stock and on March 19, 2018, a further $9,218 of the January 2018 Convertible Loans were
converted at a conversion price of $0.01 per shares into 921,800 shares of the Company’s common stock.



From
January 31, 2018 through March 23, 2018, the Company received an aggregate amount of $1,769,950 from the sale to accredited investors
of 25,285,000 of the Company’s units, at an offering price of $0.07 per unit, with each unit consisting of: (i) one share
of the Company’s common stock; and (ii) one common stock purchase warrant, exercisable for a period of twenty-four months,
to purchase one additional share of the Company’s common stock, at an exercise price of $0.14 per share. On April 16, 2018,
after the quarter ended March 31, 2018, the Company received an additional $150,000 from the sale of the units at $0.07 per unit,
pursuant to which the Company issued an additional 2,142,857 units.



On
February 8, 2018 the Company issued 571,429 shares of its common stock to two accredited investors in consideration for $80,000,
which was paid by these investors prior to December 31, 2017.



8







On
March 12, 2018, the Company issued a total of 3,629,999 restricted shares to certain consultants in connection with services rendered
during the first quarter of 2018, which shares were valued at $901,902, based on the closing share price on the day prior to each
of the issuances.



On
March 20, 2018, the Company issued a total of 1,092,500 restricted shares of its common stock as follows: (i) 62,500 shares were
issued to an accredited investor in connection with the exercise of a stock option at an exercise price of $0.01 per share, which
options were granted in connection with a services rendered in October 2016; (ii) 300,000 restricted shares were issued to Yair
Fudim, the Company’s CEO and Chairman, pursuant to a services agreement, which shares were valued at $0.01 per share and
do not vest and are not deemed earned until February 2019 under the agreement; and (iii) 730,000 restricted shares were issued
to an accredited investor in connection with services under a six-month services agreement, which shares were valued at $124,100,
based on the closing share price on the day prior to the execution of the agreement.



The
offer and sale of the Company’s units and shares of common stock to accredited investors referenced above, without registration
under the Securities Act of 1933, as amended (the “Act”), was made in reliance upon the exemption provided under Section
4(2) of the Act and/or Regulation S and/or Regulation D promulgated thereunder.



ITEM
3. DEFAULTS UPON SENIOR SECURITIES



None.



ITEM
4. MINE SAFETY DISCLOSURE



Not
applicable.



ITEM
5. OTHER INFORMATION



On
January 23, 2018, $3,000 of the Notes was converted at $0.01 per share into 300,000 shares, based upon the Notes conversion price
of $0.01 per share of common stock. On January 24, 2018, $73,000 of the January 2018 Convertible Notes were converted at a conversion
price of $0.01 per share into 7,300,000 shares of the Company’s common stock and on March 19, 2018, a further $9,218 of
the January 2018 Convertible Loans were converted at a conversion price of $0.01 per shares into 921,800 shares of the Company’s
common stock.



ITEM
6. EXHIBITS



(a)
The following documents are filed as exhibits to this Quarterly Report or incorporated by reference herein.







|Exhibit
        Number |  | Description                                                                                                                                                                                                                                                                                                                       
|---------------------- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|2.1±                   |  | Share Exchange Agreement, dated as of March 15, 2015, among the Company, Emerald Medical Applications Ltd. and the shareholders of the Company as set forth on the signature pages to the agreement (Incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K, filed with the SEC on March 16, 2015).
|                       |  |                                                                                                                                                                                                                                                                                                                                   
|3.1                    |  | Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form S-1, filed with the SEC on August 8, 2017).                                                                                                                                                 
|                       |  |                                                                                                                                                                                                                                                                                                                                   
|3.2                    |  | Certificate of Amendment to the Certificate of Incorporation of the Company, reflecting name change to Zaxis International, Inc. (Incorporated by reference to Exhibit 3.1(a) to the Company’s Registration Statement on Form S-1, filed with the SEC on August 8, 2015).                                                         
|                       |  |                                                                                                                                                                                                                                                                                                                                   
|3.3                    |  | Certificate of Amendment to the Certificate of Incorporation of the Company, reflecting reverse stock split (Incorporated by reference to Exhibit 3.1(b) to the Company’s Registration Statement on Form S-1, filed with the SEC on August 8, 2015).                                                                              
|                       |  |                                                                                                                                                                                                                                                                                                                                   
|3.4*                   |  | Certificate of Amendment to the Certificate of Incorporation of the Company, reflecting name change to Virtual Crypto Technologies, Inc.                                                                                                                                                                                          
|                       |  |                                                                                                                                                                                                                                                                                                                                   
|3.5                    |  | Bylaws of the Company (Incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form S-1, filed with the SEC on August 8, 2017).                                                                                                                                                                       
|                       |  |                                                                                                                                                                                                                                                                                                                                   
|3.6                    |  | Certificate of Designation of the Company for Series A Preferred Convertible Stock (Incorporated by reference to Exhibit 10.42 to the Company’s Current Report on Form 8-K, filed with the SEC on September 1, 2017).                                                                                                             
|                       |  |                                                                                                                                                                                                                                                                                                                                   
|4.1                    |  | Form of Class A Warrant Agreement (Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, Amendment No. 1, filed with the SEC on July 15, 2015).                                                                                                                                                   
|                       |  |                                                                                                                                                                                                                                                                                                                                   
|4.2                    |  | Form of Class E Warrant Agreement (Incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K, Amendment No. 1, filed with the SEC on July 15, 2015).                                                                                                                                                   
|                       |  |                                                                                                                                                                                                                                                                                                                                   
|4.3                    |  | Form of Class B Warrant Agreement (Incorporated by reference to Exhibit 4.2 to the Company’s Registration Statement on Form S-1, filed with the SEC on August 8, 2015).                                                                                                                                                           
|                       |  |                                                                                                                                                                                                                                                                                                                                   
|4.4                    |  | Form of Class C Warrant Agreement (Incorporated by reference to Exhibit 4.3 to the Company’s Registration Statement on Form S-1, filed with the SEC on August 8, 2015).                                                                                                                                                           
|                       |  |                                                                                                                                                                                                                                                                                                                                   
|10.1                   |  | Loan Agreement, dated as of February 2, 2015, between the Company and Emerald Medical Applications Ltd. (Incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed with the SEC on February 3, 2015).                                                                                          



9







|10.2     |  | Loan Agreement, dated as of March 19, 2015, between the Company and Emerald Medical Applications Ltd. (Incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K, filed with the SEC on March 24, 2015).                          
|-------- |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|         |  |                                                                                                                                                                                                                                                               
|10.3     |  | Loan Agreement, dated as of June 2, 2015, between the Company and Emerald Medical Applications Ltd. (Incorporated by reference to Exhibit 10.8 to the Company’s Current Report on Form 8-K, filed with the SEC on June 5, 2015).                              
|         |  |                                                                                                                                                                                                                                                               
|10.4     |  | Form of Look-Up Agreement between the Company and Selling Securityholders and Class B Warrant Holders (Incorporated by reference to Exhibit 10.10 to the Company’s Registration Statement on Form S-1, filed with the SEC on August 5, 2015).                 
|         |  |                                                                                                                                                                                                                                                               
|10.5     |  | Equity Purchase Agreement, dated as of May 12, 2016, between the Company and Kodiak Capital Group LLC (Incorporated by reference to Exhibit 10.20 to the Company’s Current Report on Form 8-K, filed with the SEC on May 18, 2016).                           
|         |  |                                                                                                                                                                                                                                                               
|10.6     |  | Registration Rights Agreement, dated as of May 12, 2016, between the Company and Kodiak Capital Group LLC (Incorporated by reference to Exhibit 10.21 to the Company’s Current Report on Form 8-K, filed with the SEC on May 18, 2016).                       
|         |  |                                                                                                                                                                                                                                                               
|10.7     |  | Securities Purchase Agreement, dated as of June 20, 2016, between the Company and Alpha Capital Anstalt (Incorporated by reference to Exhibit 10.22 to the Company’s Current Report on Form 8-K, filed with the SEC on June 22, 2016).                        
|         |  |                                                                                                                                                                                                                                                               
|10.8     |  | Registration Rights Agreement, dated as of June 20, 2016, between the Company and Alpha Capital Anstalt (Incorporated by reference to Exhibit 10.23 to the Company’s Current Report on Form 8-K, filed with the SEC on June 22, 2016).                        
|         |  |                                                                                                                                                                                                                                                               
|10.9     |  | Convertible Note in the principal amount of $400,000, dated as of June 20, 2016, issued to Alpha Capital Anstalt (Incorporated by reference to Exhibit 10.24(i) to the Company’s Current Report on Form 8-K, filed with the SEC on June 22, 2016).            
|         |  |                                                                                                                                                                                                                                                               
|10.10    |  | Convertible Note in the principal amount of $40,000, dated as of June 20, 2016, issued to Alpha Capital Anstalt (Incorporated by reference to Exhibit 10.24(ii) to the Company’s Current Report on Form 8-K, filed with the SEC on June 22, 2016).            
|         |  |                                                                                                                                                                                                                                                               
|10.11    |  | Security Agreement, dated as of June 20, 2016, between the Company, Emerald Medical Applications Ltd. and Alpha Capital Anstalt (Incorporated by reference to Exhibit 10.27 to the Company’s Current Report on Form 8-K, filed with the SEC on June 22, 2016).
|         |  |                                                                                                                                                                                                                                                               
|10.12    |  | Securities Purchase Agreement, dated July 7, 2016, between the Company and Firstfire Global Opportunities Fund (Incorporated by reference to Exhibit 10.30 to the Company’s Current Report on Form 8-K, filed with the SEC on July 29, 2016).                 
|         |  |                                                                                                                                                                                                                                                               
|10.13    |  | Registration Rights Agreement, dated as of July 7, 2016, between the Company and Firstfire Global Opportunities Fund (Incorporated by reference to Exhibit 10.31 to the Company’s Current Report on Form 8-K, filed with the SEC on July 29, 2016).           
|         |  |                                                                                                                                                                                                                                                               
|10.14    |  | Convertible Note in the principal amount of $100,000, dated as of July 7, 2016, issued to Firstfire Global Opportunities Fund (Incorporated by reference to Exhibit 10.32 to the Company’s Current Report on Form 8-K, filed with the SEC on July 29, 2016).  
|         |  |                                                                                                                                                                                                                                                               
|10.15    |  | Settlement Agreement, dated August as of 7, 2017, among the Company and Alpha Capital Anstalt and Chi Squared Capital, Inc. (Incorporated by reference to Exhibit 10.37 to the Company’s Current Report on Form 8-K, filed with the SEC on September 1, 2017).
|         |  |                                                                                                                                                                                                                                                               
|10.16    |  | Secured Convertible Note due June 20, 2019 issued by the Company to Alpha Anstalt Capital (Incorporated by reference to Exhibit 10.38 to the Company’s Current Report on Form 8-K, filed with the SEC on September 1, 2017).                                  
|         |  |                                                                                                                                                                                                                                                               
|10.17    |  | Secured Convertible Note due June 20, 2019 issued by the Company to Chi Squared Capital, Inc. (Incorporated by reference to Exhibit 10.39 to the Company’s Current Report on Form 8-K, filed with the SEC on September 1, 2017).                              
|         |  |                                                                                                                                                                                                                                                               
|10.18    |  | Class A Warrants issued by the Company on June 20, 2016 to Alpha Anstalt Capital (Incorporated by reference to Exhibit 10.40 to the Company’s Current Report on Form 8-K, filed with the SEC on September 1, 2017).                                           
|         |  |                                                                                                                                                                                                                                                               
|10.19    |  | Class A Warrants issued by the Company on June 20, 2016 to Chi Squared Capital, Inc. (Incorporated by reference to Exhibit 10.41 to the Company’s Current Report on Form 8-K, filed with the SEC on September 1, 2017).                                       
|         |  |                                                                                                                                                                                                                                                               
|10.20†*  |  | Services Agreement, dated as of February 15, 2018, between the Company and Yair Fudim.                                                                                                                                                                        
|         |  |                                                                                                                                                                                                                                                               
|31.1*    |  | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act.                                                                                                                                                               
|         |  |                                                                                                                                                                                                                                                               
|31.2*    |  | Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act.                                                                                                                                                               
|         |  |                                                                                                                                                                                                                                                               
|32.1**   |  | Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                                                                                        
|         |  |                                                                                                                                                                                                                                                               
|32.2**   |  | Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                                                                                        
|         |  |                                                                                                                                                                                                                                                               
|101.INS£ |  | XBRL
    Instance Document                                                                                                                                                                                                                                    
|         |  |                                                                                                                                                                                                                                                               
|101.INS£ |  | XBRL
    Taxonomy Extension Schema Document                                                                                                                                                                                                                   
|         |  |                                                                                                                                                                                                                                                               
|101.CAL£ |  | XBRL
    Taxonomy Extension Calculation Linkbase Document                                                                                                                                                                                                     
|         |  |                                                                                                                                                                                                                                                               
|101.DEF£ |  | XBRL
    Taxonomy Extension Definition Linkbase Document                                                                                                                                                                                                      
|         |  |                                                                                                                                                                                                                                                               
|101.LAB£ |  | XBRL
    Taxonomy Extension Label Linkbase Document                                                                                                                                                                                                           
|         |  |                                                                                                                                                                                                                                                               
|101.PRE£ |  | XBRL
    Taxonomy Extension Presentation Linkbase Document                                                                                                                                                                                                    
|         |  |                                                                                                                                                                                                                                                               
|†        |  | Management
    contract or compensatory plan or arrangement required to be filed as an exhibit pursuant to the requirements of Item 15(a)(3)
    of Form 10-K.                                                                                                
|         |  |                                                                                                                                                                                                                                                               
|*        |  | Filed
    herewith.                                                                                                                                                                                                                                           
|         |  |                                                                                                                                                                                                                                                               
|**       |  | Furnished
    herewith.                                                                                                                                                                                                                                       
|         |  |                                                                                                                                                                                                                                                               
|±        |  | Schedules
    have been omitted pursuant to Item 601(b)(ii) of Regulation S-K. A copy of any omitted schedule will be furnished supplementally
    to the SEC upon request.                                                                                   
|         |  |                                                                                                                                                                                                                                                               
|£        |  | To be filed by an amendment
                                         to this Quarterly Report.                                                                                                                                                                



10











SIGNATURES



Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersignedthereunto duly authorized.



|                       | VIRTUAL CRYPTO TECHNOLOGIES, INC.
|---------------------- | ---------------------------------
|                       |                                  
|                       | By:                              
|                       | Name:                            
|                       | Title:                           
|Date:
    May 21, 2018 |                                  





|                       | By:    | /s/
    Gadi Levin                                                
|---------------------- | ------ | ------------------------------------------------------------------
|                       | Name:  | Gadi
    Levin                                                    
|                       | Title: | Chief
    Financial Officer                                       
|                       |        | (Principal
    Financial Officer and Principal Accounting Officer)
|Date:
    May 21, 2018 |        |                                                                   





11